Stem Point Capital LP Portfolio Holdings

Stem Point Capital LP

  • $378 Billion
  • Q1 2024

Stem Point Capital LP has filed its 13F form on May 13, 2024 for Q1 2024 where it was disclosed a total value porftolio of $378 Billion distributed in 63 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Roivant Sciences Ltd. with a value of $37.5B, Crinetics Pharmaceuticals, Inc. with a value of $29B, Syndax Pharmaceuticals Inc with a value of $26.2B, Arcutis Biotherapeutics, Inc. with a value of $21.9B, and Immunovant, Inc. with a value of $20.3B.

Examining the 13F form we can see an increase of $3.5B in the current position value, from $375B to 378B.

Stem Point Capital LP is based out at New York, NY

Below you can find more details about Stem Point Capital LP portfolio as well as his latest detailed transactions.

Portfolio value $378 Billion
Healthcare: $315 Billion
ETFs: $876 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$7.5B
$37.5 Billion 9.9% of portfolio
3,553,844
Q1 2024 Added 63.84%
$2.36B
$29 Billion 7.67% of portfolio
619,789
Q1 2024 Added 148.34%
$1.18B
$26.2 Billion 6.93% of portfolio
1,100,988
Q1 2024 Added 0.59%
$631M
$21.9 Billion 5.78% of portfolio
2,205,899
Q1 2024 Reduced 14.98%
$3.55B
$20.3 Billion 5.36% of portfolio
627,228
Q1 2024 Added 94.78%
$314M
$18.9 Billion 5.0% of portfolio
2,965,721
Q1 2024 Added 557.04%
$2.81B
$18.2 Billion 4.82% of portfolio
1,547,141
Q1 2024 Added 79.31%
$205M
$17.1 Billion 4.53% of portfolio
1,003,916
Q1 2024 Added 122.74%
$290M
$13.8 Billion 3.64% of portfolio
1,161,060
Q1 2024 Added 174.37%
$217M
$13.7 Billion 3.63% of portfolio
2,017,016
Q1 2024 Added 122.35%
$869B
$11.7 Billion 3.1% of portfolio
15,067
Q4 2023 New
$2.45B
$10.5 Billion 2.78% of portfolio
233,871
Q1 2024 Reduced 53.39%
$2.37B
$9.76 Billion 2.58% of portfolio
140,267
Q1 2024 Reduced 55.27%
Vistagen Therapeutics Inc
-
$9.29 Billion 2.46% of portfolio
-
Q1 2024 Added 3.26%
$743M
$8.08 Billion 2.14% of portfolio
222,253
Q1 2024 Added 617.18%
$102M
$7.64 Billion 2.02% of portfolio
1,794,195
Q1 2024 New
Tourmaline Bio Inc
-
$6.28 Billion 1.66% of portfolio
-
Q1 2024 New
Anaptysbio Inc
-
$6.07 Billion 1.6% of portfolio
-
Q1 2024 Added 499.0%
$328M
$5.62 Billion 1.49% of portfolio
740,877
Q1 2024 Reduced 5.4%
$895M
$5.17 Billion 1.37% of portfolio
491,926
Q1 2024 Reduced 51.78%
Soleno Therapeutics Inc
-
$4.96 Billion 1.31% of portfolio
-
Q1 2024 New
Acelyrin Inc
-
$4.82 Billion 1.28% of portfolio
-
Q1 2024 Added 21.69%
$1.66B
$4.58 Billion 1.21% of portfolio
121,642
Q1 2024 New
Biohaven LTD
-
$4.56 Billion 1.21% of portfolio
-
Q1 2024 Reduced 25.05%
$1.55B
$4.55 Billion 1.2% of portfolio
90,647
Q1 2024 Reduced 46.0%
$214M
$4.34 Billion 1.15% of portfolio
605,117
Q1 2024 Reduced 0.33%
$322M
$3.84 Billion 1.02% of portfolio
407,108
Q1 2024 Added 8.11%
$1.65B
$3.83 Billion 1.01% of portfolio
87,393
Q1 2024 New
Jasper Therapeutics Inc
-
$3.79 Billion 1.0% of portfolio
-
Q1 2024 New
Avadel Pharmaceuticals PLC
-
$3.78 Billion 1.0% of portfolio
-
Q1 2024 New
Disc Medicine Inc
-
$3.74 Billion 0.99% of portfolio
-
Q1 2024 Reduced 52.06%
$100M
$3.12 Billion 0.83% of portfolio
1,087,785
Q1 2024 New
$138M
$2.68 Billion 0.71% of portfolio
230,273
Q1 2024 Reduced 73.13%
Spyre Therapeutics Inc
-
$2.36 Billion 0.62% of portfolio
-
Q1 2024 Reduced 83.56%
Helix Acquisition Corp Ii
-
$2.08 Billion 0.55% of portfolio
-
Q1 2024 New
Effector Therapeutics Inc
-
$1.91 Billion 0.51% of portfolio
-
Q1 2024 New
-
$1.9 Billion 0.5% of portfolio
-
Q1 2024 New
Cg Oncology Inc
-
$1.79 Billion 0.47% of portfolio
-
Q1 2024 New
$33.8M
$1.73 Billion 0.46% of portfolio
1,385,750
Q1 2024 New
Praxis Precision Medicines I
-
$1.64 Billion 0.43% of portfolio
-
Q1 2024 New
Dianthus Therapeutics Inc
-
$1.3 Billion 0.34% of portfolio
-
Q1 2024 New
Cargo Therapeutics Inc
-
$1.14 Billion 0.3% of portfolio
-
Q1 2024 Added 90.24%
Kyverna Therapeutics Inc
-
$1.02 Billion 0.27% of portfolio
-
Q1 2024 New
$23.3M
$675 Million 0.18% of portfolio
168,442
Q1 2024 New

Summary

  • Portfolio
  • No. of Stocks 63
  • Current Value $378 Billion
  • Prior Value $375 Billion
  • Filing
  • Period Q1 2024
  • Filing Date May 13, 2024
  • Form Type 13F-HR
  • Activity in Q1 2024
  • New Purchases 17 stocks
  • Additional Purchases 16 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 11 stocks
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email